fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Libtayo (cemiplimab) for advanced basal cell carcinoma

Written by | 21 Jul 2020

Article written by Christine Clark At present there are no approved treatments for advanced basal cell carcinoma, a condition that is estimated to affect about 20,000 US patients… read more.

Phase I/II COV001 trial of AZD 1222 shows vaccine well tolerated in SARS-CoV-2 virus.- AstraZeneca

Written by | 21 Jul 2020

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD 1222 vaccine, from AstraZeneca, was tolerated and generated robust immune responses against the… read more.

Trial of SNG 001 shows positive results in COVID-19 patients.- Synairgen

Written by | 21 Jul 2020

Synairgen announced positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised COVID-19 patients. The double-blind placebo-controlled trial recruited 101 patients… read more.

Phase III trial of BXCL 501 meets endpoints in patients with agitation and schizophrenia and bipolar disorder.- BioXcel Therapeutics

Written by | 21 Jul 2020

BioXcel Therapeutics announced that BXCL 501 (sublingual dexmedetomidine), met the primary and secondary endpoints of SERENITY I and SERENITY II, demonstrating a robust treatment effect in the trials… read more.

Bellerophon Therapeutics announces publication of cohort 1 of iNO-PF phase II/III study in the CHEST Journal and participation in webinar to discuss clinical results

Written by | 21 Jul 2020

Bellerophon Therapeutics, Inc. announced that results from Cohort 1 of the iNO-PF Phase II/III Study will be published in the August 2020 edition of the peer-reviewed CHEST Journal,… read more.

FDA grants emergency use authorisation for xMAP SARS-CoV-2 Multi-Antigen IgG Assay in Coronavirus.- Luminex Corp

Written by | 21 Jul 2020

Luminex Corporation announced that the FDA has issued an Emergency Use Authorization (EUA) for the company’s xMAP SARS-CoV-2 Multi-Antigen IgG Assay. Clinical laboratories can now use this serology… read more.

Pfizer and BioNTech announce early positive update from German phase 1/II COVID-19 vaccine study, of BNT 162 mRNA-based vaccine, including first T cell response data.

Written by | 21 Jul 2020

BioNTech SE and Pfizer Inc announced initial data from their ongoing German Phase 1/II, open-label, non-randomized, non-placebo-controlled, dose-escalation trial , that is part of the global mRNA-based vaccine… read more.

FDA approves phase II trial of AC 0010MA in COVID-19.- Sorrento Therapeutics

Written by | 21 Jul 2020

Sorrento Therapeutics received clearance from the FDA to initiate a Phase II trial of AC 0010MA (abivertinib) in patients with COVID-19 who have moderate to severe pulmonary symptoms…. read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.